CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
In a significant diplomatic and economic shift, the Trump administration has agreed to slash tariffs on Indian goods after securing a commitment from New Delhi to phase out purchases of Russian crude oil.
Novo Nordisk's experimental combination therapy CagriSema has demonstrated superior blood sugar control and weight loss compared to its own blockbuster Wegovy in a major Phase 3 trial. However, the emerging data suggests it may still trail behind Eli Lilly's rival drug Zepbound in key efficacy measures, setting the stage for a fierce market battle.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
Fosun International's stock has tumbled over 14% in the last 90 days, reigniting the debate over the Chinese conglomerate's true worth. With shares trading at HK$4.12 against a widely cited fair value of HK$5.77, analysts are divided on whether this is a moment of market overreaction or a sign of deeper structural challenges.
Adobe and Cognizant are expanding their strategic partnership to help major corporations integrate generative AI into content creation and customer experience workflows. The move targets regulated, high-growth industries grappling with soaring demand for personalized content, positioning Adobe's tools as enterprise-ready solutions amid investor scrutiny over its stock performance.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Fourth-quarter earnings for S&P 500 companies are significantly outperforming expectations, led by robust growth in industrial and tech sectors, as investors await a busy week of corporate results and key economic data.
While AI's role in headline-grabbing discoveries like AlphaFold is celebrated, Anthropic is forging a new path. Through partnerships with the Allen Institute and HHMI, the company is embedding Claude AI into the unglamorous, time-consuming groundwork of research—betting that efficiency gains in data analysis and coordination will compress decades of scientific progress.
AIGH Capital Management has liquidated its entire position in semiconductor firm MaxLinear, a move that coincides with the chipmaker's recent strong quarterly earnings report, raising questions about the fund's strategy.
While Viatris shares have edged past the broader market over the past year, analysts maintain a guarded stance, balancing solid fundamentals against recent profitability pressures and a mixed earnings record.
While October's COLA announcement brings temporary relief, a growing body of evidence suggests the formula used to calculate Social Security adjustments fails to reflect the real-world expenses of retirees, creating a persistent and compounding budget gap.
The grocery sector begins 2026 with significant executive turnover, including leadership changes at Lidl US, The Save Mart Companies, and a major realignment within Walmart's top ranks ahead of its CEO transition.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
